| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -304,742 | -201,309 |
| Depreciation and amortization | 3,911 | 2,537 |
| Stock-based compensation expense | 38,428 | 26,051 |
| Net accretion of discount on marketable securities | 5,442 | 3,768 |
| Loss (gain) on disposal of property and equipment | -304 | -5 |
| Non-cash operating lease expense | 9,229 | 6,094 |
| Expense associated with license agreement | 10,000 | 10,000 |
| Realized gain on investments | 0 | 2 |
| Gain on sale of contingent payments | 0 | - |
| Milestone payment from gain on sale of oncology business | 0 | - |
| Accounts receivable, net | 920 | 877 |
| Inventory | 4,418 | 3,232 |
| Prepaid expenses and other current and non-current assets | 2,227 | 3,746 |
| Accounts payable | 2,891 | 1,084 |
| Accrued expenses and other current liabilities | -9,644 | -11,572 |
| Income taxes payable | -871 | -871 |
| Operating lease liabilities | -12,473 | -8,228 |
| Other non-current liabilities | -790 | -779 |
| Net cash used in operating activities | -276,764 | -188,613 |
| Purchases of marketable securities | 480,681 | 305,700 |
| Proceeds from maturities and sales of marketable securities | 780,985 | 508,894 |
| Payments associated with license agreement | 10,000 | 10,000 |
| Proceeds from sale of contingent payments | 0 | - |
| Proceeds from milestone payment from gain on sale of oncology business | 0 | - |
| Purchases of property and equipment | 3,196 | 1,641 |
| Proceeds from sale of equipment | 0 | 0 |
| Net cash provided by investing activities | 287,108 | 191,553 |
| Net proceeds from stock option exercises and employee stock purchase plan | 6,119 | 1,684 |
| Net cash provided by financing activities | 6,119 | 1,684 |
| Net change in cash and cash equivalents | 16,463 | 4,624 |
| Cash and cash equivalents at beginning of period | 76,247 | - |
| Cash and cash equivalents at end of period | 92,710 | - |
AGIOS PHARMACEUTICALS, INC. (AGIO)
AGIOS PHARMACEUTICALS, INC. (AGIO)